2/5
06:08 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
2/5
01:28 pm
ocul
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
Medium
Report
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
2/5
10:58 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/5
07:18 am
ocul
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
2/5
07:17 am
ocul
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
Low
Report
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
2/5
07:00 am
ocul
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Medium
Report
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2/4
07:46 am
ocul
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
Low
Report
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
1/23
04:01 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/21
07:00 am
ocul
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Low
Report
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
1/15
06:42 am
ocul
3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]
High
Report
3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]
1/7
05:38 pm
ocul
Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]
1/2
06:15 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]
12/31
11:30 am
ocul
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]
Low
Report
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]
12/9
08:19 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
12/8
11:41 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
12/8
07:03 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
07:00 am
ocul
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
High
Report
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
12/6
09:27 am
ocul
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]
High
Report
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]
12/5
07:00 am
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/25
08:07 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
11/24
07:00 am
ocul
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
Low
Report
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
11/24
02:05 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at
Wall Street
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at
Wall Street
11/18
12:49 am
ocul
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]
Low
Report
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]
11/16
01:10 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at
Wall Stre
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at
Wall Stre
11/14
11:21 am
ocul
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? [Yahoo! Finance]
Low
Report
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? [Yahoo! Finance]